- cafead Feb 13, 2022 at 12:03: AM
via If omicron remains the dominant coronavirus strain, it's possible that omicron-specific versions of vaccines could enjoy greater future demand compared to rival vaccines that don't specifically target the variant. In this segment from "This Week in Healthcare," recorded on Jan. 31, Motley Fool contributors Brian Orelli and Keith Speights discuss how vaccine makers Moderna (NASDAQ:MRNA) and Pfizer (NYSE
FE) are preparing for this possibility with their new clinical trials.
article source
FE) are preparing for this possibility with their new clinical trials.article source